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Abstract: 
 
This article describes the development of a new fluorescent-engineered human calmodulin, 
hCaM M124C–mBBr, useful in the identification of potential calmodulin (CaM) inhibitors. 
An hCaM mutant containing a unique cysteine residue at position 124 on the protein was 
expressed, purified, and chemically modified with the fluorophore monobromobimane (mBBr). 
The fluorophore-labeled protein exhibited stability and functionality to the activation of 
calmodulin-sensitive cAMP phosphodiesterase (PDE1) similar to wild-type hCaM. The hCaM 
M124C–mBBr is highly sensitive to detecting inhibitor interaction given that it showed a 
quantum efficiency of 0.494, approximately 20 times more than the value for wild-type hCaM, 
and a large spectral change (∼80% quenching) when the protein is in the presence of saturating 
inhibitor concentrations. Two natural products previously shown to act as CaM inhibitors, 
malbrancheamide (1) and tajixanthone hydrate (2), and the well-known CaM inhibitor 
chlorpromazine (CPZ) were found to quench the hCaM M124C–mBBr fluorescence, and the 
IC50 values were comparable to those obtained for the wild-type protein. These results support 
the use of hCaM M124C–mBBr as a fluorescence biosensor and a powerful analytical tool in the 
high-throughput screening demanded by the pharmaceutical and biotechnology industries. 
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Article: 
 
Calmodulin (CaM)1 is a small Ca2+-modulated protein of 148 amino acids (16,706 Da) 
considered as the primary transducer of Ca2+-mediated signals in eukaryotes. It has four motifs 
called EF hands (each bind a single Ca2+ ion) that are composed of two α-helices linked by a 12-
residue loop. CaM amino acid sequence is highly conserved in animal and plants, although the 
latter organisms express several CaM isoforms. 
 
CaM acts on many cellular targets, including soluble enzymes, ion channels, and primary pumps, 
resulting in a variety of essential downstream cellular effects [1], [2], [3], [4], [5], [6]. 
Accordingly, this protein influences a number of important physiological processes representing 
an important drug target [7]. Indeed, many CaM inhibitors are well-known antipsychotic smooth 
muscle relaxants, antitumoral and α-adrenergic blocking agents, among others. The interaction of 
CaM with its physiological targets depends on the exposure of two hydrophobic pockets (Fig. 1) 
following the conformational change elicited by Ca2+ binding to the protein. 
 
 
Fig. 1. Three-dimensional structures of CaM in its different conformations: (A) calcium free 
(Protein Data Bank [PDB] code: 1CFD); (B) with calcium (PDB code: 1CLL); (C) with TFP 
(PDB code: 1LIN). The structures were drawn using the PyMOL program [38]. 
 
Many compounds, including drugs, pesticides, and research tools, interact with CaM at the same 
hydrophobic sites also provoking conformational changes in the protein. Many of these 
substances behave as CaM antagonists, the best-known structural examples of these interactions 
are the antipsychotic analogs of trifluoroperazine (TFP) (Fig. 1) [8]. Such interactions can be 
detected using several analytical methods, including affinity chromatography, ultraviolet (UV), 
circular dichroism (CD) spectroscopy [9], gel electrophoresis [10], [11], nuclear magnetic 
resonance (NMR) [12], [13], X-ray diffraction [8], [14], [15], [16], functional enzymatic 
assays [17], [18], [19], and fluorescence-based technologies such as fluorescence resonance 
energy [20], [21], [22], [23]. The fluorescence-based methods are highly specific, low cost, 
selective, and they have rapid reaction time, although sometimes the preparation of the sensing 
element can be laborious. Among the fluorescence-based methods, the use of site-selective 
fluorescently labeled CaM has become popular recently. In addition, these methods have been 
demonstrated to be a powerful biosensing system for screening certain classes of drugs such as 
tricyclic antidepressants [24]. One of the most widely used procedures involves the covalent 
attachment to CaM of a thiol-reactive fluorophore strategically located using site-directed 
cysteine mutagenesis. With such a molecular probe, it is possible to correlate the conformational 
changes with ligand binding by the changes in the emission properties of the labeled proteins. 
 
In previous investigations, it has been determined that the attachment of different fluorophores at 
the cysteine residue located at position 109 produced better extrinsic fluoresce enhancement on 
ligand binding [25]. Here we describe the development of a fluorescence-based assay useful for 
detecting potential CaM inhibitors using a fluorescent human CaM (hCaM). The protein was 
engineered by rational design, replacing Met124 by cysteine using site-directed mutagenesis; the 
resulting protein, hCaM M124C, was purified by hydrophobic exchange chromatography and 
monobromobimane (mBBr) was attached covalently to Cys124 as fluorescent probe. The 
fluorophore mBBr was selected because of its high sensitivity. Such sensitivity has been 
successfully exploited in the elucidation of the secondary structure of T4 lysozyme [26]. The 
stability and functionality of hCaM M124C–mBBr (hCaM labeled with mBBr at position 124) 
were determined by CD measurement and functional enzymatic assay using calmodulin-
sensitive cAMP phosphodiesterase (PDE1) as a monitor enzyme. Furthermore, the usefulness 
of hCaM M124C–mBBr was demonstrated by testing the ability of the known CaM inhibitors 
malbrancheamide (1), tajixanthone hydrate (2) [27], [28], and chlorpromazine (CPZ) (Fig. 2) to 
quench the fluorescence of the engineered protein and to inhibit CaM–PDE1 complex. 
 
 
Fig. 2. Structures of compounds 1, 2, and CPZ. The structures were drawn with ChemBioDraw 
software (version 11.0, CambridgeSoft, http://www.cambridgesoft.com). 
 
Materials and methods 
 
Reagents 
 
CALM1 (human phosphorylase kinase, delta) gene was purchased from Origene Technology 
(Rockville, MD, USA). pGEM-T Easy Vector System I was purchased from Promega (Madison, 
WI, USA). pET12b vector was obtained from Novagen (Darmstadt, Germany). Pfu DNA 
polymerase was purchased from Stratagene (La Jolla, CA, USA). NdeI and BamHI were 
obtained from New England Biolabs (Ipswich, MA, USA). Primers for polymerase chain 
reaction (PCR) mutagenesis and Escherichia coli BL21-AI One Shot were purchased from 
Invitrogen (Carlsbad, CA, USA). mBBr was purchased from Toronto Chemical Research 
(Toronto, Canada). All other reagents were of analytical reagent grade and were purchased from 
Sigma (St. Louis, MO, USA). 
 
Subclonig of gene encoding for hCaM and site-directed mutagenesis 
 
CALM1 gene encoding hCaM was amplified using PCR from the complementary DNA (cDNA) 
clone pCMV6-XL5 (Origene Technology) along with the primers (5′-
CATATGGCTGATCAGCTGACCG-3′ and 5′-CCTAGGAGTAAAACGTCAGTAGT AGAC-
3′) to insert restriction sites NdeI and BamHI at the start and end of the gene. Amplified products 
were cloned into a vector (pGEM-T Easy Vector System I) and further subcloned into the protein 
expression vector pET12b Novagen (EMD Chemicals, Darmstadt, Germany). Single amino acid 
substitutions were generated by overlapping PCR mutagenesis using the Quick Change Kit 
(Stratagene). All clones and mutations were confirmed by nucleotide sequencing with an ABI 
PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). In all cases, the 
single methionine at position 124 in the wild-type sequences was replaced by cysteine to 
facilitate conjugation of the reporter group to this thiol. Plasmids were transformed into E. 
coli BL21-AI One Shot following the specifications of the kit’s manufacturer. 
 
Protein purification of hCaM and the mutant hCaM M124C 
 
A single colony of E. coli strain BL21-AI/pET12b was grown in Luria–Bertani (LB) medium 
containing 100 mg/ml of ampicillin overnight with shaking at 37 °C and was inoculated into 
500 ml of LB medium containing 100 mg/ml of ampicillin until the optical density (OD) of the 
culture at 550 nm reached between 0.8 and 1.0. Expression was induced by the addition of l-(+)-
arabinose (0.2%, w/v) overnight with shaking at 37 °C. The cells were harvested by 
centrifugation (10 min, 4000g), resuspended in 50 mM Tris–HCl, 2 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), and 200 mg/ml of egg 
white lysozyme at pH 7.5 and were chilled on ice for 30 min. Resuspended cells were lysed by 
sonication, and cellular debris was removed by centrifugation for 15 min at 15,000g. The 
supernatant was collected, and CaCl2 and NaCl were added to final concentrations of 5 and 
500 mM, respectively. The protein was purified using a Phenyl Sepharose CL-4B 
chromatographic column. Briefly, the supernatant was applied to the column preequilibrated 
with 50 mM Tris–HCl, 0.5 mM DTT, 0.1 mM CaCl2, and 500 mM NaCl at pH 7.5. The column 
was washed with loading buffer, followed by the same with 1 mM EDTA and 150 mM NaCl. 
Finally, the protein was loaded on a cationic exchange column (Source Q, Amersham 
Biosciences, Piscataway, NJ, USA) at pH 8.8 and was eluted by a linear gradient of 40 min (0–
100%) with 500 mM NaCl. Protein was collected in fractions and assessed for purity by gel 
electrophoresis. All preparations were at least 98% pure by this criterion (Fig. 3). 
 
 
Fig. 3. Purification of hCaM M124C by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE) and line profiles. Line 1: molecular weight standard proteins; line 
2: supernatant of lysate; line 3: fraction nonbound at Phenyl Sepharose CL-4B column; line 4: 
fraction bound at Phenyl Sepharose CL-4B column; line 5: hCaM after cationic exchange 
column. The densitometric profiles were obtained using ImageJ software 
(http://rsb.info.nih.gov/ij). 
 
Chemical modification of unique reactive cysteine of hCaM M124C protein with mBBr 
 
All fluorophore conjugations steps were typically carried out at room temperature. To a protein 
at a concentration of 5 to 10 mg/ml, 5 mM was added and incubated for 3 h to reduce 
intramolecular disulfide bonds, and then it was washed on a gel filtration HR-100 column 
(Pharmacia Biotech, Piscataway, NJ, USA). A thiol-reactive fluorophore (20% in dimethyl 
sulfoxide [DMSO]) was added in small aliquots to reach a final concentration of 10 molar excess 
and DMSO of approximately 5%. Conjugation proceeded in the dark overnight at 4 °C. 
Separation of protein from unreacted fluorophore was achieved by size exclusion 
chromatography (Superdex 75). The efficiency of report group attachment was assessed by 
reactivity of the protein against 5-5′-dithiobis-(2-nitrobenzoic) acid (DTNB), measuring the 
release of 2-nitrobenzoate (TNB). Next, protein concentrations of both wild-type and 
labeled hCaM were determined with the bicinchoninic acid method [29]. 
 
Circular dichroism 
 
CD wavelength scans and thermal melting data were recorded on a JASCO J-715 
spectropolarimeter under an N2 atmosphere with an attached thermal Peltier temperature control 
module. Thermal denaturation of hCaM wild-type and hCaM M124C–mBBr was monitored at 
222 nm with a resolution step of 0.5 °C, a bandwidth of 1.0 nm, and a response time of 16 s. The 
concentration of protein used was 5 μM in 100 mM sodium phosphate buffer (pH 5.1). The 
sample was heated at a rate of 60 °C/h from 20 to 90 °C. Data were analyzed using the spectra 
manager software (version 1.50.00) supplied with the instrument and using a nonlinear 
regression analysis to a two-state model with the Origin 7.0 program (OriginLab, Northampton, 
MA, USA): 
 
𝜃𝜃 = (𝜃𝜃N+𝑚𝑚N[𝑇𝑇])+(𝜃𝜃N+𝑚𝑚U[𝑇𝑇])𝑒𝑒
−(∆𝐻𝐻𝑚𝑚 𝑅𝑅𝑅𝑅⁄ +∆𝐻𝐻𝑚𝑚 𝑅𝑅𝑅𝑅𝑚𝑚⁄ )
1+𝑒𝑒−(∆𝐻𝐻𝑚𝑚 𝑅𝑅𝑅𝑅⁄ +∆𝐻𝐻𝑚𝑚 𝑅𝑅𝑅𝑅𝑚𝑚⁄ )
,      (1) 
 
where θN and θU represent the molar ellipticity in the native and unfolded states, 
respectively; mN and mU represent the temperature dependence of the molar ellipticity in the 
native and unfolded states, respectively; T represents temperature (K); R represents ideal gas 
constant (kcal mol–1 K–1); ΔH represents change in enthalpy (kcal mol–1 K–1); and Tm represents 
melting temperature (K). 
 
Steady-state fluorescence 
 
All measurements were conducted with an ISS–PC1 spectrofluorometer (ISS, Champaign, IL, 
USA) with sample stirring at 37 °C. The protein hCaM M124C–mBBr (5 μM) was incubated in 
buffer (100 mM phosphate [pH 5.1] and 10 mM CaCl2). Fluorescence emission spectra were 
acquired with excitation and emission slit widths of 4 and 8 nm, respectively. The excitation 
wavelength was 381 nm, and emission wavelengths of 420 to 640 nm were measured. The 
fractional degree of saturated hCaM M124C–mBBr with ligand (y) was calculated by changes in 
fluorescence on ligand binding according to y = (F − F0) / (F∞ − F0), where F∞ represents the 
fluorescence intensity at saturation of the ligand, y is plotted as a function of the inhibitor 
concentration, and the apparent dissociation constants (Kd) were obtained by fitting to Eq. (2): 
 
𝑦𝑦 = (1+𝐾𝐾d 𝑃𝑃0⁄ +𝐿𝐿0 𝑃𝑃0⁄ )−�(1+𝐾𝐾d 𝑃𝑃0⁄ +𝐿𝐿0 𝑃𝑃0⁄ )
2−4𝐿𝐿0 𝑃𝑃0⁄
2
,      (2) 
 
where y represents the fractional degree of fluorescence intensity at 470 nm, Kd is the apparent 
dissociation constant for the ligands, and P0 and L0 are the total concentrations of the protein and 
ligand, respectively. The data were analyzed using the Origin 7.0 program. 
 
hCaM–PDE1 bioassay 
 
hCaM–PDE1 assay was performed in a 96-well plate as described previously [30] with some 
modifications. Briefly, wild-type hCaM or hCaM M124C–mBBr (0.08 μg) was incubated with 
0.015 units of CaM-deficient/CaM-dependent cAMP phosphodiesterase from bovine brain for 
30 min in 40 μl of assay solution containing 0.063 units of 5′-nucleotidase, 45 mM Tris–HCl, 
5.6 mM magnesium acetate, 45 mM imidazole, 2.5 mM calcium chloride, and 10 μM bovine 
serum albumin (BSA) at pH 7.0. Test compounds were then added to the assay medium at 0.5, 1, 
2, 3, 4, 7, 13, 20, 32, 50, and 65 μM in acetonitrile (ACN)/water (1:1), and the samples were 
incubated for 30 min. After that, 10 μl of 10.8 mM cAMP was added to start the assay. After 
15 min, the assay was stopped by the addition of 190 μl of Malachite green solution. The 
phosphodiesterase reaction was coupled to the 5′-nucleotidase (Crotalus atrox venom from 
Sigma) reaction; the amount of inorganic phosphate released, measured spectrophotometrically 
at 700 nm, was correlated with the activity of the PDE1. All of the results are expressed as the 
mean of at least six experiments ± standard error of the mean (SEM). The IC50 values were 
determined by nonlinear regression analysis performed with the Origin 7.0 program as reported 
previously [28]. 
 
Results and discussion 
 
Design of a suitable site for hCaM mutagenesis 
 
The specificity of the interaction of CaM with its molecular targets and its role in the regulation 
of several biochemical processes make this protein a powerful research tool to explore its 
physiological role and a target for drug discovery. Therefore, we have specifically labeled a 
cysteine residue at 124 with mBBr, a sensitive fluorescent probe, to yield a new hCaM variant 
(Fig. 4) following a rational approach with the goal of preserving the structural and functional 
properties of the native protein. The cysteine residue was introduced exchanging Met124 by site-
directed mutagenesis. This position was selected for the following reasons. First, X-ray analyses 
of cocrystallized CaM-Ca2+–TFP complex indicated the participation of 14 side chains in the 
binding site [25], including Met124; specifically, this position interacts with two molecules of 
TFP (Fig. 4). Furthermore, when TFP binds to CaM-Ca2+, residue Met124 moves from being 
totally exposed to a buried position near the hydrophobic pocket (Fig. 4). Second, Met124 is 
located in a relative rigid α-helical region; therefore, disruption in the native fold of the protein 
for the formation of disulfide-linked aggregates is unlikely. This position also shows a large 
chemical shift change in the 1H and 13C NMR spectra when the protein is titrated with the 
inhibitor W-7 [31]. Therefore, the microenvironment surrounding position 124 is very 
susceptible to CaM inhibitors. Accordingly, attachment of a fluorophore at this position should 
report any conformational change on the inhibitor binding. Third, we carried out in silico studies 
of the modified protein using the HyperChem 7.5 program. When the structure was minimized to 
a 0.09 kcal/mol gradient with the AMBER94 force field, the linear distances from the thiol group 
of Cys124 (Cys124 SG) to N1 of each TFP molecule present in the Ca2+-CaM–TFP complex 
were 3.75 and 4.96 Å, respectively. These distances were small enough to allow fluorescent 
quenching by the inhibitors but large enough to pose no severe steric hindrance on binding of a 
medium-sized ligand. Fourth, the solvent accessibility of hCaM M124C calculated by the Lee–
Richards algorithm implemented in NACCESS 2.1.1 software [32] was 60.5 Å2; thus, the 
inclusion of a small fluorophore such as mBBr should not affect its stability [26]. In summary, 
modification at position 124 was in agreement with previous work described in the 
literature [26], [33]. 
 
 
Fig. 4. In silico model of the mutation of cysteine residue and bimane attachment (hCaM 
M124C–mBBr) created using HyperChem software (version 7.5, HyperCube, 
http://www.hyper.com), by a geometric optimization using the AMBER force field, reaching a 
minimum gradient of 0.01 kcal Ǻ–1 mol–1. Red lines show amino acid of the site binding in the 
CaM–TFP complex, green sticks show mBBr, orange sticks show TFP, and pale yellow balls 
show Ca2+. Hydrogens are omitted for clarity. 
 
The hCaM M124C was generated as described in Materials and methods and was chemically 
modified to give the corresponding hCaM M124C–mBBr. 
 
Stability and functionality of hCaM M124C–mBBr 
 
The folding, stability, and functionality of both the wild-type and mutant hCaM M124C–mBBr 
were studied by monitoring structural changes in the overall conformation using physical 
methods [34], [35] (far-UV CD) and an enzymatic assay. The percentages of secondary structure 
elements calculated from the far-UV CD spectra of both wild-type and hCaM M124C–mBBr do 
not show significant variations (84.27% α-helix and 1.24% β-structure) (Fig. 5A). The Tm values 
of wild-type hCaM and hCaM M124C–mBBr were 61 and 57 °C, respectively, suggesting 
thermal stability in both cases (Fig. 5B). The modified protein also displayed a significant 
activation of the PDE1. The IC50 values obtained for CPZ by PDE1 assays are consistent with 
those reported previously in the literature [9], [36], [37] (Table 1). 
 
 
Fig. 5. Far-UV CD spectra (A) and molar ellipticity at 222 nm (B) for Apo-hCaM WT (○) 
and hCaM M124C–mBBr (Δ). The secondary structures in the presence of Ca2+ were determined 
from CD spectra using K2D2 program [39]. Thermal denaturation for both proteins were 
monitored by the changes in molar ellipticity as a function of the temperature, from 20 to 90 °C. 
The buffer was 100 mM sodium phosphate (pH 5.1). The solid lines are the best fits using 
Eq. (1) (see Materials and methods). 
 
Table 1. Experimental IC50 values and apparent Kd values of compounds 1, 2, 
and CPZ determined by PDE1 and fluorescent assays. 
Compound hCaM WT hCaM M124C–mBBr 
IC50 (μM)a IC50 (μM)a Kd (μM)b 
1 3.65 ± 0.74 3.04 ± 0.11 0.261 ± 0.023 
2 5.62 ± 1.25 5.58 ± 0.20 0.033 ± 0.006 
CPZ 21.98 ± 1.94 19.20 ± 0.36 1.714 ± 0.184 
a Determined by PDE1 assay. 
b Determined by fluorescent assay. 
 
Titration of hCaM M124C–mBBr with compounds 1, 2, and CPZ 
 
The modified protein showed a quantum efficiency of 0.494, approximately 20 times more than 
the value for wild-type hCaM (ϕ = 0.025). hCaM M124C–mBBr displayed the largest 
fluorescence response at 470 nm (λex = 381 nm), thereby avoiding any interference due to UV 
absorption of most common ligands. 
 
Fig. 6 and Table 1 summarize the concentration-dependent effect of compounds 1, 2, 
and CPZ on the fluorescence response of hCaM M124C–mBBr. The addition of 
compound 2 and CPZ quenched the fluorescence of the engineered protein in approximately 
84%, whereas compound 1 showed a slightly smaller response (78%). In all cases, the effect 
correlated with the structural changes of the protein on binding of the inhibitor (Fig. 4, Fig. 6). 
 
 
Fig. 6. Titration by fluorescence of engineered hCaM with compounds 1 (A), 2 (B), 
and CPZ (C) (left panels). Buffer was 5 mM KAc (pH 5.1) at 37 °C and 1 mM CaCl2, and 
excitation was at 381 nm. The absolute changes of fluorescence emission at 470 nm (ΔΔIF) were 
plotted against the ratio inhibitor/protein and fitted to the binding equation model to obtain the 
fractional degree of saturated hCaM M124C–mBBr (right panels). 
 
The signal changes maximal in fluorescence (470 nm) was plotted versus the inhibitor/protein 
total ratio, and the fitting curves provided an apparent Kd (see Materials and methods). 
The Kd of CPZ was similar to that reported previously for antagonists of the CaM [40]. The 
IC50 values calculated for CPZ, 1, and 2 were consistent with those previously 
reported [9], [27], [36] and those found in the current study with native hCaM (Table 1), 
providing an important evidence of the specificity of hCaM M124C–mBBr. 
 
Conclusions 
 
A new fluorescent-engineered hCaM, hCaM M124C–mBBr, has been designed by a 
combination of site-directed mutagenesis and covalent attachment of a fluorophore probe. The 
protein is stable and functional for activation of PDE1 and shows promise for detecting new 
CaM inhibitors in a reliable, quick, and sensitive manner. The fluorophore-labeled protein 
detects classic CaM inhibitors such as CPZ and was used strategically for reevaluating two 
natural products. Its efficacy was demonstrated by means of a functional enzymatic assay and by 
fluorescence spectroscopy. Finally, hCaM M124C–mBBr can be used as an important tool for 
identifying new CaM inhibitors that will be useful as potential drugs or pesticides. Another 
possibility not tested in this work is to use hCaM M124C–mBBr to detect new potential protein–
protein interactions given that this protein conserved functionality to interact with PDE1. 
 
Acknowledgments 
 
This work was supported by grants from Dirección General de Asuntos del Personal Académico 
(DGAPA, IN216207) and Consejo Nacional de Ciencia y Tecnologia (CONACyT, 53633 and 
41328Q). The technical assistance of Isabel Rivero-Cruz is also recognized. M.G.A. 
acknowledges a fellowship for Ph.D. studies from CONACyT. 
 
References 
 
[1] E. Carafoli, C.B. Klee, Calcium as a Cellular Regulator, Oxford University Press, New York, 
1999. 
 
[2] M. Zhang, T. Yuan, Molecular mechanisms of calmodulin’s functional versatility, Biochem. 
Cell Biol. 76 (1998) 313–323. 
 
[3] H. Weinstein, E.L. Mehler, Ca2+-binding and structural dynamics in the functions of 
calmodulin, Annu. Rev. Physiol. 56 (1994) 213–236. 
 
[4] R.E. Zielinski, Calmodulin and calmodulin-binding proteins in plants, Annu. Rev. Plant 
Physiol. Plant Mol. Biol. 49 (1998) 697–725. 
 
[5] K.T. O’Neil, W.F. DeGrado, How calmodulin binds its targets: sequence independent 
recognition of amphiphilic a-helices, Trends Biochem. Sci. 15 (1990) 59–64. 
 
[6] M.J. Berridge, M.D. Bootman, H.L. Roderick, Calcium signalling: dynamics, homeostasis, 
and remodelling, Nat. Rev. Mol. Cell Biol. 4 (2003) 517–529. 
 
[7] R. Dagher, C. Pigault, D. Bonnet, D. Boeglin, C. Pourbaix, M.C. Kilhoffer, P. Villa, C.G. 
Wermuth, M. Hibert, J. Haiech, Use of a fluorescent polarization based high throughput assay to 
identify new calmodulin ligands, Biochim. Biophys. Acta 1763 (2006) 1250–1255. 
 
[8] B.G. Vertessy, V. Harmat, Z. Bocskei, G. Naray-Szabo, F. Orosz, J. Ovadi, Simultaneous 
binding of drugs with different chemical structures to Ca2+– calmodulin: crystallographic and 
spectroscopic studies, Biochemistry 37 (1998) 15300–15310. 
 
[9] S. Martinez-Luis, A. Perez-Vasquez, R. Mata, Natural products with calmodulin inhibitor 
properties, Phytochemistry 68 (2007) 1882–1903. 
 
[10] M. Charpenteau, K. Jaworski, B.C. Ramirez, A. Tretyn, R. Ranjeva, B. Ranty, A receptor-
like kinase from Arabidopsis thaliana is a calmodulin-binding protein, Biochem. J. 379 (2004) 
841–848. 
 
[11] B. Liao, M.C. Gawienowski, R.E. Zielinski, Differential stimulation of NAD kinase and 
binding of peptide substrates by wild-type and mutant plant calmodulin isoforms, Arch. 
Biochem. Biophys. 327 (1996) 53–60. 
 
[12] J.J. Chou, S. Li, A. Bax, Study of conformational rearrangement and refinement of 
structural homology models by the use of heteronuclear dipolar couplings, J. Biomol. NMR 18 
(2000) 217–227. 
 
[13] D.J. Lalor, T. Schnyder, V. Saridakis, D.E. Pilloff, A. Dong, H. Tang, T.S. Leyh, E.F. Pai, 
Structural and functional analysis of a truncated form of Saccharomyces cerevisiae ATP 
sulfurylase: C-terminal domain essential for oligomer formation but not for activity, Protein Eng. 
16 (2003) 1071–1079. 
 
[14] R. Chattopadhyaya, W.E. Meador, A.R. Means, F.A. Quiocho, Calmodulin structure refined 
at 1.7 Å resolution, J. Mol. Biol. 228 (1992) 1177–1192. 
 
[15] H. Kuboniwa, N. Tjandra, S. Grzesiek, H. Ren, C.B. Klee, A. Bax, Solution structure of 
calcium-free calmodulin, Nat. Struct. Biol. 2 (1995) 768–776. 
 
[16] T. Okubo, S. Okada, Kinetic analyses of colloidal crystallization in alcoholic organic 
solvents and their aqueous mixtures as studied by reflection spectroscopy, J. Colloid Interface 
Sci. 204 (1998) 198–204. 
 
[17] S.P. Chock, C.Y. Huang, An optimized continuous assay for cAMP phosphodiesterase and 
calmodulin, Anal. Biochem. 138 (1984) 34–43. 
 
[18] A.C. Harmon, H.W. Jarrett, M.J. Cormier, An enzymatic assay for calmodulins based on 
plant NAD kinase activity, Anal. Biochem. 141 (1984) 168–178. 
 
[19] R.K. Sharma, J.H. Wang, Preparation and assay of the Ca2+-dependent modulator protein, 
Adv. Cyclic Nucleotide Res. 10 (1979) 187–198. 
 
[20] M.W. Allen, R.J. Urbauer, A. Zaidi, T.D. Williams, J.L. Urbauer, C.K. Johnson, 
Fluorescence labeling, purification, and immobilization of a double cysteine mutant calmodulin 
fusion protein for single-molecule experiments, Anal. Biochem. 325 (2004) 273–284. 
 
[21] B. Sharma, S.K. Deo, L.G. Bachas, S. Daunert, Competitive binding assay using 
fluorescence resonance energy transfer for the identification of calmodulin antagonists, Bioconj. 
Chem. 16 (2005) 1257–1263. 
 
[22] E. Dikici, S.K. Deo, S. Daunert, A whole-cell assay for the high throughput screening of 
calmodulin antagonists, Anal. Bioanal. Chem. 390 (2008) 2073–2079. 
 
[23] J.P. Gangopadhyay, Z. Grabarek, N. Ikemoto, Fluorescence probe study of Ca2+- dependent 
interactions of calmodulin with calmodulin-binding peptides of the ryanodine receptor, Biochem. 
Biophys. Res. Commun. 323 (2004) 760–768. 
 
[24] P.M. Douglass, L.L. Salins, E. Dikici, S. Daunert, Class-selective drug detection: 
fluorescently-labeled calmodulin as the biorecognition element for phenothiazines and tricyclic 
antidepressants, Bioconj. Chem. 13 (2002) 1186–1192. 
 
[25] L.C. Vesna Schauer-Vukasinovic, S. Daunert, Rational design of a calcium sensing system 
based on induced conformational change of calmodulin, J. Am. Chem. Soc. 119 (1997) 11102–
11103. 
 
[26] S.E. Mansoor, H.S. McHaourab, D.L. Farrens, Determination of protein secondary structure 
and solvent accessibility using site-directed fluorescence labeling: studies of T4 lysozyme using 
the fluorescent probe monobromobimane, Biochemistry 38 (1999) 16383–16393. 
 
[27] M. Figueroa, M.C. González, R. Rodríguez-Sotres, A. Sosa-Peinado, M. González-Andrade, 
C.M. Cerda-García-Rojas, R. Mata, Calmodulin inhibitors from the fungus Emericella sp., 
Bioorg. Med. Chem. (in press), doi:10.1016/j.bmc.2008.10.079. 
 
[28] S. Martínez-Luis, L. Acevedo, M.C. González, R. Rodríguez-Sotres, A. Lira-Rocha, R. 
Mata, Malbrancheamide, a new calmodulin inhibitor from the fungus Malbranchea aurantiaca, 
Tetrahedron 62 (2006) 1817–1822. 
 
[29] P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, 
E.K. Fujimoto, N.M. Goeke, B.J. Olson, D.C. Klenk, Measurement of protein using 
bicinchoninic acid, Anal. Biochem. 150 (1985) 76–85. 
 
[30] B. Rivero-Cruz, I. Rivero-Cruz, R. Rodriguez-Sotres, R. Mata, Effect of natural and 
synthetic benzyl benzoates on calmodulin, Phytochemistry 68 (2007) 1147–1155. 
 
[31] M. Osawa, M.B. Swindells, J. Tanikawa, T. Tanaka, T. Mase, T. Furuya, M. Ikura, Solution 
structure of calmodulin–W-7 complex: the basis of diversity in molecular recognition, J. Mol. 
Biol. 276 (1998) 165–176. 
 
[32] B. Lee, F.M. Richards, The interpretation of protein structures: Estimation of static 
accessibility, J. Mol. Biol. 55 (1971) 379–400. 
 
[33] R.M. de Lorimier, J.J. Smith, M.A. Dwyer, L.L. Looger, K.M. Sali, C.D. Paavola, S.S. 
Rizk, S. Sadigov, D.W. Conrad, L. Loew, H.W. Hellinga, Construction of a fluorescent 
biosensor family, Protein Sci. 11 (2002) 2655–2675. 
 
[34] R.R. Biekofsky, S.R. Martin, J.E. McCormick, L. Masino, S. Fefeu, P.M. Bayley, J. Feeney, 
Thermal stability of calmodulin and mutants studied by 1H–15N HSQC NMR measurements of 
selectively labeled [15N] Ile proteins, Biochemistry 41 (2002) 6850–6859. 
 
[35] L. Masino, S.R. Martin, P.M. Bayley, Ligand binding and thermodynamic stability of a 
multidomain protein, calmodulin, Protein Sci. 9 (2000) 1519–1529. 
 
[36] S.Z. Khan, C.L. Longland, F. Michelangeli, The effects of phenothiazines and other 
calmodulin antagonists on the sarcoplasmic and endoplasmic reticulum Ca2+ pumps, Biochem. 
Pharmacol. 60 (2000) 1797–1806. 
 
[37] M. Figueroa, M.C. González, R. Mata, Malbrancheamide B, a novel compound from the 
fungus Malbranchea aurantiaca, Nat. Prod. Res. 22 (2008) 709–714. 
 
[38] J.D. Johnson, L.A. Wittenauer, A fluorescent calmodulin that reports the binding of 
hydrophobic inhibitory ligands, Biochem. J. 211 (1983) 473–479. 
 
[39] W.L. DeLano, Use of PYMOL as a communications tool for molecular science, Abstracts 
Papers Am. Chem. Soc. 228 (2004) U313–U314. 
 
[40] M.A. Andrade, P. Chacon, J.J. Merelo, F. Moran, Evaluation of secondary structure of 
proteins from UV circular dichroism spectra using an unsupervised learning neural network, 
Protein Eng. 6 (1993) 383–390. 
